Crucell « Terug naar discussie overzicht

FD: Fortune vindt Crucell topper

25 Posts, Pagina: « 1 2 | Laatste
aossa
0
quote:

Crucial schreef:

klopt inderdaad.....raar gedoe daar!
Link naar het artikel voor de ongelovige Tomassen !
www.fd.nl/ShowNews.asp?Context=N%7C3&...

Gratis registreren noodzakelijk.
Snel want straks verdwijnt het van de site !
pim f
0
quote:

giraf+4 schreef:

janh1:

de vergelijking met de dubbeldekkers vind ik geweldig. Die houden we er in.

Giraf
wel beetje jammer in deze vergelijking dat het nieuwste van het nieuwste supervliegtuig (Airbus A380) ook een dubbeldekker is, dus ik wilde deze vergelijking maar niet aanbevelen
jokus
2

Zopas een artikel gelezen van de beheerders van PRIVAK KBC Biotech fonds uit belgië. Er zat geen enkel bedrijf uit de benelux in hun portefeuille !!??
"Omdat de schaarse aandelen hen niet kon bekoren"!!?? In Nederland geloven we niet in de mogelijkheden van Pharming, en Crucell vinden we te duur, omdat het bedrijf vooral een produktieplatvorm is !!??

Ik denk dat Mhr.Devenijns en Mvr.Amerijckx van deze Privak toch eerst eens wat meer op onderzoek moeten gaan naar wat Pharming en Crucell te bieden hebben ! Wat een lullige en oppervlakkige verklaring van zulke mensen zeg??

Al goed dat ik m'n geld niet in dit Kbc privak gestopt heb, zulke amateurs !!
[verwijderd]
1
Het bericht van Fortune:

25 BREAKOUT COMPANIES 2005

Crucell
Technology: Cells for vaccine production
Sector: Biotech
Headquarters: Leiden, Holland
Website: www.crucell.com

If the deadly bird flu simmering in Southeast Asia boils up into a pandemic, demand for influenza vaccines will explode. So will Crucell's stock price. The company offers a line of human cells that's emerging as a key ingredient for making the vaccines. Currently vaccine production entails growing flu viruses in fertilized chicken eggs; the viruses are extracted, deactivated, and processed into flu shots. The eggs come from high-tech poultry farms that would be hard to expand fast. Boosting vaccine production with Crucell's methods would be relatively easy—its cells, in which flu viruses thrive, are kept in big vats called bioreactors that can be readily multiplied to expand capacity.
Recently the U.S. government awarded $97 million to Sanofi Pasteur, the vaccine unit of Sanofi Aventis, to fund its transition to Crucell technology for making flu vaccines in the U.S. The process is also being used to develop vaccines for malaria, Ebola virus, and West Nile virus. Crucell is hawking its technology to make many other bioengineered medicines too. A raft of drugmakers, including GlaxoSmithKline and Roche, have licensed its "PER.C6" cells for that purpose. If enough customers follow suit, Crucell's investors won't have to wait for a flu pandemic to see the stock take off. — David Stipp

[verwijderd]
0
Ik heb het mooie FORTUNE ARTIKEL over CRUCELL al diverse malen gelezen! het blijft boeien! ...explode...so will Crucell's stock price.
gr
janh

quote:

WY schreef:

Het bericht van Fortune:

25 BREAKOUT COMPANIES 2005

Crucell
Technology: Cells for vaccine production
Sector: Biotech
Headquarters: Leiden, Holland
Website: www.crucell.com

If the deadly bird flu simmering in Southeast Asia boils up into a pandemic, demand for influenza vaccines will explode. So will Crucell's stock price. The company offers a line of human cells that's emerging as a key ingredient for making the vaccines. Currently vaccine production entails growing flu viruses in fertilized chicken eggs; the viruses are extracted, deactivated, and processed into flu shots. The eggs come from high-tech poultry farms that would be hard to expand fast. Boosting vaccine production with Crucell's methods would be relatively easy—its cells, in which flu viruses thrive, are kept in big vats called bioreactors that can be readily multiplied to expand capacity.
Recently the U.S. government awarded $97 million to Sanofi Pasteur, the vaccine unit of Sanofi Aventis, to fund its transition to Crucell technology for making flu vaccines in the U.S. The process is also being used to develop vaccines for malaria, Ebola virus, and West Nile virus. Crucell is hawking its technology to make many other bioengineered medicines too. A raft of drugmakers, including GlaxoSmithKline and Roche, have licensed its "PER.C6" cells for that purpose. If enough customers follow suit, Crucell's investors won't have to wait for a flu pandemic to see the stock take off. — David Stipp

25 Posts, Pagina: « 1 2 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
911,51  -3,44  -0,38%  21 mei
 Germany40^ 18.741,40 +0,08%
 BEL 20 3.991,00 -0,40%
 Europe50^ 5.050,10 +0,06%
 US30^ 39.880,20 0,00%
 Nasd100^ 18.717,30 0,00%
 US500^ 5.322,81 0,00%
 Japan225^ 38.868,40 0,00%
 Gold spot 2.422,05 -0,17%
 EUR/USD 1,0857 -0,02%
 WTI 78,62 -0,74%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

Flow Traders +3,27%
SBM Offshore +2,38%
OCI +2,13%
INPOST +1,82%
Eurocommercia... +1,56%

Dalers

Alfen N.V. -15,53%
Sif Holding -6,63%
AMG Critical ... -5,70%
Avantium -4,78%
EBUSCO HOLDING -4,44%